Grants per year
Personal profile
Research Interests
My primary research interest is in lung repair after acute injury with a focus on TGF-beta mediated signaling. We have identified mitochondrial generated reactive oxygen species as important in TGF-bête mediated gene expression and are working to identify novel therapeutic targets in this pathway. We are also interested in modulating the ubiquitin-proteosomal pathway as a therapeutic target for tissue fibrosis. I have a clinical translational interest in Cystic Fibrosis. I am the site co-PI for the CF Foundation sponsored clinical trial network, The Therapeutic Development Network. I am also interested in the CF outcomes, especially related to chronic infection with Pseudomonas aeruginosa.
Certifications and Licenses
| Pulmonary Disease | |
| Internal Medicine | |
| Critical Care Medicine |
Training Experience
| 1990 | Internship, University of Chicago Pritzker School of Medicine |
| 1992 | Residency, Univ. of Chicago Hospital |
| 1996 | Fellowship, University of Chicago |
Education/Academic qualification
Medicine, MD, University of Chicago
… → 1989
Research interests
- Critical Care
- Cystic Fibrosis
- Fibrosis
- Lungs / Breathing Problems
- TGF-beta
Fingerprint
Dive into the research topics where Manu Jain is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #VX20-121-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Resi
Vertex Pharmaceuticals Incorporated
1/25/22 → 1/25/25
Project: Research project
-
Prot #VX20-121-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Vertex Pharmaceuticals Incorporated
12/13/21 → 12/13/24
Project: Research project
-
-
-
Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis
Rohani, R., Hoff, B., Jain, M., Philbrick, A., Salama, S., Cullina, J. F. & Rhodes, N. J., Mar 2022, In: European Journal of Drug Metabolism and Pharmacokinetics. 47, 2, p. 199-209 11 p.Research output: Contribution to journal › Article › peer-review
-
Barriers and facilitators to implementing telehealth services during the COVID-19 pandemic: A qualitative analysis of interviews with cystic fibrosis care team members
Van Citters, A. D., Dieni, O., Scalia, P., Dowd, C., Sabadosa, K. A., Fliege, J. D., Jain, M., Miller, R. W. & Ren, C. L., Dec 2021, In: Journal of Cystic Fibrosis. 20, p. 23-28 6 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Bronchoscopy on intubated patients with COVID-19 is associated with low infectious risk to operators
NU COVID Investigators, Jul 2021, In: Annals of the American Thoracic Society. 18, 7, p. 1243-1246 4 p.Research output: Contribution to journal › Letter › peer-review
Open Access18 Scopus citations -
Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia
The NU SCRIPT Study Investigators, Feb 25 2021, In: Nature. 590, 7847, p. 635-641 7 p.Research output: Contribution to journal › Article › peer-review
Open Access157 Scopus citations -
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation
GOAL-e2 Investigators, Mar 2021, In: Journal of Cystic Fibrosis. 20, 2, p. 213-219 7 p.Research output: Contribution to journal › Article › peer-review
13 Scopus citations